p21-/- mice exhibit enhanced bone regeneration after injury

BMC Musculoskelet Disord. 2017 Nov 9;18(1):435. doi: 10.1186/s12891-017-1790-z.

Abstract

Background: p21(WAF1/CIP1/SDI1), a cyclin dependent kinase inhibitor has been shown to influence cell proliferation, differentiation and apoptosis; but more recently, p21 has been implicated in tissue repair. Studies on p21(-/-) knockout mice have demonstrated results that vary from complete regeneration and healing of tissue to attenuated healing. There have however been no studies that have evaluated the role of p21 inhibition in bone healing and remodeling.

Methods: The current study employs a burr-hole fracture model to investigate bone regeneration subsequent to an injury in a p21-/- mouse model. p21-/- and C57BL/6 mice were subjected to a burr-hole fracture on their proximal tibia, and their bony parameters were measured over 4 weeks via in vivo μCT scanning.

Results: p21-/- mice present with enhanced healing from week 1 through week 4. Differences in bone formation and resorption potential between the two mouse models are assessed via quantitative and functional assays. While the μCT analysis indicates that p21-/- mice have enhanced bone healing capabilities, it appears that the differences observed may not be due to the function of osteoblasts or osteoclasts. Furthermore, no differences were observed in the differentiation of progenitor cells (mesenchymal or monocytic) into osteoblasts or osteoclasts respectively.

Conclusions: Therefore, it remains unknown how p21 is regulating enhanced fracture repair and further studies are required to determine which cell type(s) are responsible for this regenerative phenotype.

Keywords: Bone healing; Mice; Trabecular bone; p21; μCT.

MeSH terms

  • Animals
  • Bone Regeneration*
  • Cyclin-Dependent Kinase Inhibitor p21 / physiology*
  • Female
  • Male
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Osteogenesis
  • Tibial Fractures
  • X-Ray Microtomography

Substances

  • Cyclin-Dependent Kinase Inhibitor p21

Grants and funding